United StatesHealth

Veru (NASDAQ:VERU) announced its fiscal 2025 results and provided updates on its clinical development of enobosarm for obesity treatment on December 17, 2025.

GSK (NYSE:GSK) announced the U.S. Food and Drug Administration (FDA) approval of Exdensur (depemokimab), a novel, long-acting biologic treatment for severe asthma with an eosinophilic phenotype.

Nyxoah (NASDAQ:NYXH) announced the successful commercial launch of its Genio bilateral neurostimulation system in the Netherlands on Dec. 17, 2025.

INNOVATE Corp. (NYSE:VATE) said MediBeacon, in which it holds a 44.7% equity stake, has received U.S. Food and Drug Administration approval for its next-generation MediBeacon TGFR System, introducing a reusable sensor intended to broaden access to point-of-care kidney function assessment.

Rezolve Ai (NASDAQ:RZLV) expects to exceed $17 million in revenue for December 2025, with annual recurring revenue (ARR) set to surpass $200 million by year-end.

Monte Rosa Therapeutics (NASDAQ:GLUE) reported encouraging early clinical results for its molecular glue degrader MRT-2359 in combination with enzalutamide, showing pronounced activity in a genetically defined subset of heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

Tonix Pharmaceuticals (NASDAQ:TNXP) has secured exclusive worldwide rights to TNX-4900, a selective small-molecule Sigma-1 receptor antagonist positioned as a potential new treatment for chronic neuropathic pain.

Corteva (NYSE:CTVA), the agricultural technology giant, and Hexagon Bio, a biotechnology company focused on nature-derived therapeutics, announced a multi-million-dollar joint venture aimed at accelerating the discovery of new crop protection solutions.

Cosette Pharmaceuticals said the U.S. Food and Drug Administration has approved its abbreviated new drug application for the first generic version of CIPRO HC, granting the company 180 days of Competitive Generic Therapy exclusivity and ending a more than 27-year stretch without a generic alternative.

Royalty Pharma (NASDAQ:RPRX) said it has acquired a royalty interest in two of Nuvalent’s lead cancer programs for as much as $315 million, adding long-dated exposure to a pair of next-generation tyrosine kinase inhibitors targeting ALK- and ROS1-altered non-small cell lung cancer.